To side with the contrarian study aforementioned, if firms can’t charge whatever they want to cover their costs and satisfy investors, then Eli and Pfizer drugs like this won’t come to the market too often, or soon enough to matter for those who need them.
Moderna is another relevant example: one-trick covid vaccine pony who’ll fade into obscurity unless they hit again with life-changing product. Only difference is that governments paid for their products not patients.
https://www.wsj.com/health/healthcare/new-pancreatic-cancer-mutation-treatment-7b066368